Analysis of behavior-related adverse experiences in clinical trials of montelukast


      Frequencies of behavior-related adverse experiences (BRAEs) in controlled clinical studies of leukotriene modifier drugs have not been summarized.


      We sought to compare the frequency of BRAEs in patients receiving montelukast or placebo in a retrospective analysis of Merck clinical trial data.


      An adverse experience database was constructed to include all double-blind, placebo-controlled trials of montelukast meeting prespecified criteria. BRAEs (described using the Medical Dictionary for Regulatory Activities controlled vocabulary dictionary) were prespecified to include any term in the Psychiatric Disorders System Organ Class, selected terms related to general disorders, and terms related to akathisia. Frequencies of BRAEs (overall, leading to study discontinuation, and/or serious) were summarized. Analyses estimated the odds ratios (ORs) for montelukast versus placebo based on the frequency of patients with BRAEs in each study.


      In total 35 adult and 11 pediatric placebo-controlled trials were included; 11,673 patients received montelukast, 8,827 received placebo, and 4,724 received active control. The frequency of patients with 1 or more BRAEs was 2.73% and 2.27% in the montelukast and placebo groups, respectively; the OR for montelukast versus placebo was 1.12 (95% CI, 0.93-1.36). The frequency of patients with a BRAE leading to study discontinuation was 0.07% and 0.11% in the montelukast and placebo groups, respectively (OR, 0.52; 95% CI, 0.17-1.51). The frequency of patients with a BRAE considered serious was 0.03% in both treatment groups.


      Reports of BRAEs were infrequent in clinical trials of montelukast. Those leading to study discontinuation or considered serious were rare. Frequencies were similar regardless of treatment group.

      Key words

      Abbreviations used:

      AE (Adverse experience), Akath-PT (Akathisia-related preferred term), BRAE (Behavior-related adverse experience), CNS (Central nervous system), CysLT1, (Cysteinyl leukotriene type 1), CysLT (Cysteinyl leukotriene), FDA (US Food and Drug Administration), HLGT (High-level Group Term), MedDRA (Medical Dictionary for Regulatory Activities), OR (Odds ratio), OtherSelect-PT (Other selected behavior-related preferred term), PT (Preferred Term), Psych-SOC (Psychiatric Disorders System Organ Class), SMQ (Standardized MedDRA query), SOC (System Organ Class)
      To read this article in full you will need to make a payment


      1. SINGULAIR (montelukast sodium) prescribing information [package insert]. Whitehouse Station (NJ): Merck & Co, Inc., 2009.

        • Kewalramani A.
        • Bollinger M.E.
        • Postolache T.T.
        Asthma and mood disorders.
        Int J Child Health Hum Dev. 2008; 1: 115-123
        • Scott K.M.
        • Von Korff M.
        • Ormel J.
        • Zhang M.
        • Bruffaerts R.
        • Alonso J.
        • et al.
        Mental disorders among adults with asthma: results from the World Mental Health Survey.
        Gen Hosp Psychiatry. 2007; 29: 123-133
        • Chun T.H.
        • Weitzen S.H.
        • Fritz G.K.
        The asthma/mental health nexus in a population-based sample of the United States.
        Chest. 2008; 134: 1176-1182
        • Strine T.W.
        • Mokdad A.H.
        • Balluz L.S.
        • Gonzalez O.
        • Crider R.
        • Berry J.T.
        • et al.
        Depression and anxiety in the United States: findings from the 2006 Behavioral Risk Factor Surveillance System.
        Psychiatric Services. 2008; 59: 1383-1390
        • Blackman J.A.
        • Gurka M.J.
        Developmental and behavioral comorbidities of asthma in children.
        J Dev Behav Pediatr. 2007; 28: 92-99
        • Katon W.
        • Lozano P.
        • Russo J.
        • McCauley E.
        • Richardson L.
        • Bush T.
        The prevalence of DSM-IV anxiety and depressive disorders in youth with asthma compared with controls.
        J Adolesc Health. 2007; 41: 455-463
      2. US Food and Drug Administration. Early communication about an ongoing safety review of montelukast (SINGULAIR), March 27, 2008. Available at: Accessed August 10, 2009.

      3. US Food and Drug Administration. Update of safety review follow-up to the March 27, 2008, communication about the ongoing safety review of montelukast (SINGULAIR), January 13, 2009. Available at: Accessed August 10, 2009.

      4. US Food and Drug Administration. Updated information on leukotriene inhibitors: montelukast (marketed as Singulair), zafirlukast (marketed as Accolate), and zileuton (marketed as Zyflo and Zyflo CR), June 12, 2009. Available at: Accessed August 10, 2009.

        • Zelen M.
        The analysis of several 2x2 contingency tables.
        Biometrika. 1971; 58: 129-137
      5. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance: drug safety information—FDA's communication to the public, March 2007. Available at: Accessed August 10, 2009.

        • Postolache T.T.
        • Lapidus M.
        • Sander E.R.
        • Langenberg P.
        • Hamilton R.G.
        • Soriano J.J.
        • et al.
        Changes in allergy symptoms and depression scores are positively correlated in patients with recurrent mood disorders exposed to seasonal peaks in aeroallergens.
        Sci World J. 2007; 17: 1968-1977
        • Bell I.
        • Jasnoski M.
        • Kagan J.
        • King D.
        Depression and allergies: survey of a nonclinical population.
        Psychother Psychosom. 1991; 55: 24-31
        • Hurwitz E.L.
        • Morgenstern H.
        Cross-sectional associations of asthma, hay fever, and other allergies with major depression and low-back pain among adults aged 20–39 years in the United States.
        Am J Epidemiol. 1999; 150: 1107-1116
        • Timonen M.
        • Jokelainen J.
        • Silvennoinen-Kassinen S.
        • Herva A.
        • Zitting P.
        • Xu B.
        • et al.
        Association between skin test diagnosed atopy and professionally diagnosed depression: a Northern Finland 1966 Birth Cohort study.
        Biol Psychiatry. 2002; 52: 349-355
        • Timonen M.
        • Jokelainen J.
        • Hakko H.
        • Silvennoinen-Kassinen S.
        • Meyer-Rochow V.P.
        • Herva A.
        • et al.
        Atopy and depression: results from the Northern Finland 1966 Birth Cohort Study.
        Mol Psychiatry. 2003; 8: 738-744
        • Timonen M.
        • Jokelainen J.
        • Herva A.
        • Zitting P.
        • Meyer-Rochow V.P.
        • Räsänen P.
        Presence of atopy in first-degree relatives as a predictor of a female proband's depression: Results from the Northern Finland 1966 Birth Cohort.
        J Allergy Clin Immunol. 2003; 111: 1249-1254
        • Goodwin R.D.
        • Castro M.
        • Kovacs M.
        Major depression and allergy: does neuroticism explain the relationship?.
        Psychosom Med. 2006; 68: 94-98
      6. ADVAIR® DISKUS® 100/50 (fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder) prescribing information [package insert]. Research Triangle Park (NC): GlaxoSmithKline, 2009.

      7. FLOVENT® DISKUS® 50 mcg (fluticasone propionate inhalation powder, 50 mcg) prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2008.

      8. PULMICORT FLEXHALER™ (budesonide) Aerosol, Powder prescribing information. Wilmington (DE): AstraZeneca LP, 2008.

        • Strauss A.
        • Gould A.L.
        • Nelsen L.M.
        • Wiholm B.E.
        • Jones J.K.
        Public-released version of the Adverse Event Reporting System (AERS) database.
        Clin Ther. 2005; 27 ([letter]) (author reply 357-9): 355-357
      9. The Institute for Safe Medication Practices. QuarterWatch: 2008 Quarter 2. Available at: Accessed August 10, 2009.

      10. US Food and Drug Administration. Potential signals of serious risks/new safety information identified by the Adverse Event Reporting System (AERS). February 4, 2009. Available at: Accessed August 10, 2009.

        • Brunlöf G.
        • Tukukino C.
        • Wallerstedt S.M.
        Individual case safety reports in children in commonly used drug groups—signal detection.
        BMC Clin Pharmacol. 2008; 8: 1
        • Holbrook J.T.
        • Harik-Khan R.
        Montelukast and emotional well-being as a marker for depression: results from three randomized, double-masked clinical trials.
        J Allergy Clin Immunol. 2008; 122: 828-829
        • Van Lieshout R.J.
        • Bienenstock J.
        • MacQueen G.M.
        A review of the pathways underlying the association between asthma and major depressive disorder.
        Psychosom Med. 2009; 71: 187-195
        • Lynch K.R.
        • O'Neill G.P.
        • Liu Q.
        • Im D.-S.
        • Sawyer N.
        • Metters K.M.
        • et al.
        Characterization of the human cysteinyl leukotriene CysLT1 receptor.
        Nature. 1999; 399: 789-883
        • Jones T.R.
        • Labelle M.
        • Belley M.
        • Champion E.
        • Charette L.
        • Evans J.
        • et al.
        Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist [published erratum in: Can J Physiol Pharmacol 1995;73:747].
        Can J Physiol Pharmacol. 1995; 73: 191-201
        • Fang S.H.
        • Wei E.Q.
        • Zhou Y.
        • Wang M.L.
        • Zhang W.P.
        • Yu G.L.
        • et al.
        Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats.
        Neuroscience. 2006; 140: 969-979
        • Ciana P.
        • Fumagalli M.
        • Trincavelli M.L.
        • Verderio C.
        • Rosa P.
        • Lecca D.
        • et al.
        The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor.
        EMBO J. 2006; 25: 4615-4627
        • Lecca D.
        • Trincavelli M.L.
        • Gelosa P.
        • Sironi L.
        • Ciana P.
        • Fumagalli M.
        • et al.
        The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
        PLoS ONE. 2008; 3 (e3579)
        • Peters-Golden M.
        • Henderson Jr., W.R.
        N Engl J Med. 2007; 357: 1841-1854
        • Uz T.
        • Dimitrijevic N.
        • Tueting P.
        • Manev H.
        5-lipoxygenase (5LOX)-deficient mice express reduced anxiety-like behavior.
        Restor Neurol Neurosci. 2002; 20: 15-20
        • Uz T.
        • Dimitrijevic N.
        • Imbesi M.
        • Manev H.
        • Manev R.
        Effects of MK-866, a 5-liopoxygenase activating protein (FLAP) inhibitor, and 5-lipoxygenase deficiency on the forced swimming behavior of mice.
        Neurosci Lett. 2008; 436: 269-272
        • Uz T.
        • Dwivedi Y.
        • Pandey G.N.
        • Roberts R.C.
        • Conley R.R.
        • Manev R.
        • et al.
        5-Lipoxygenase in the prefrontal cortex of suicide victims.
        Open Neuropsychopharmacol J. 2008; 1: 1-5

      Linked Article

      • Correction
        Journal of Allergy and Clinical ImmunologyVol. 125Issue 5
        • Preview
          With regard to the October 2009 article entitled “Analysis of behavior-related adverse experiences in clinical trials of montelukast” (J Allergy Clin Immunol 2009;124:699-706), two protocol numbers in Table E1 are incorrect as given. Under “Adult Studies,” protocol number “202” should read “A202,” and protocol number “402” should read “A402.”
        • Full-Text
        • PDF